Regeneron reported stronger-than-expected second-quarter revenue growth, yet faced FDA regulatory delays tied to manufacturing issues at a Catalent facility impacting several Eylea HD applications and odronextamab approval. While optimistic about favorable future decisions post-issue resolution, the current setbacks illustrate ongoing challenges in pharma supply chain and approval processes. Additionally, Moderna CEO Stéphane Bancel reaffirmed focus on R&D partnerships over M&A amid cash burn concerns, underscoring cautious financial strategy in a competitive environment.